Venous thromboembolic disease is a common and life-threatening condition in cancer patients. Results from a recent retrospective study of 66,106 hospitalized adult neutropenic cancer patients showed that 2.74% to 12.10% of these patients, depending on the type of malignancy, experienced a venous thromboembolism (VTE) during first hospitalization. These guidelines specifically outline strategies to prevent and treat VTE in adult inpatients with either a diagnosis of cancer or for whom cancer is clinically suspected. These guidelines evaluate the therapeutic advantages of implementing pharmacologic anticoagulation measures based on both the perceived risk for bleeding (i.e., contraindications to anticoagulation) and the status of the cancer.
For the most recent version of the guidelines, please visit NCCN.org
Since its inception in 1972 as one of the nation's first comprehensive cancer centers, Duke Comprehensive Cancer Center has been at the forefront of efforts to understand, prevent, diagnose, and treat cancer through patient care, clinical research, laboratory investigation, and education. Every activity the Cancer Center undertakes— from basic research to clinical trials to educational programs— is aimed at improving the care of cancer patients. U.S. News & World Report has consistently ranked Duke among the nation's top 10 centers for cancer care and the top cancer center in the Southeast. In 2005, there were more than 7,600 discharges and 145,000 outpatient encounters for cancer care at Duke. Drawn by the Cancer Center's national and international reputation, Duke's oncology patients represent virtually every county in North Carolina and every state in the nation.
The Cancer Center's leadership team includes (left to right, second photo on the cover) Medical Director Thomas D'Amico, MD, Administrative Director Carolyn Carpenter, and Director H. Kim Lyerly, MD. Joseph Moore, MD (third photo on the cover), is a member of the nationally renown staff.